End-of-day quote Toronto S.E. 06:00:00 2024-04-23 pm EDT 5-day change 1st Jan Change
0.43 CAD -3.37% Intraday chart for Sernova Corp. -7.53% -38.57%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sernova Corp. Provides Positive Clinical and Platform Portfolio Update CI
Sernova Corp. Reports Earnings Results for the First Quarter Ended January 31, 2024 CI
Sernova Corp. Announces CFO Changes CI
Sernova Corp. Reports Earnings Results for the Full Year Ended October 31, 2023 CI
Sernova Receives Orphan Drug and Rare Pediatric Disease Designations for its Hemophilia A Program from FDA MT
Sernova Corp. Announces New Advancements of Conformal Coating Technology in Combination with the Cell Pouch System? at the 2023 IPITA-IXA-CTRMS Joint Congress CI
Sernova Announces Positive Interim Phase 1/2 Clinical Data for the Cell Pouch System for Type 1 Diabetes Trial MT
Sernova Announces Positive Ongoing Interim Phase 1/2 Clinical Data for the Cell Pouch System? for Type 1 Diabetes Trial at the 2023 IPITA, IXA, and CTRMS Joint Congress CI
Sernova Corp. Announces New Preclinical Data for its Novel Cell Therapy Platform, Cell Pouch System, as Potential Treatment for Post-Operative Hypothyroidism at 2023 American Thyroid Association Annual Meeting CI
Sernova Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023 CI
Sernova Corp. Provides Development Update on Proprietary Cellular Conformal Coating Technology in Combination with Cell Pouch Device CI
Sernova Names New CEO, Former CEO Assumes Tech Chief Role MT
Sernova Corp. Announces Executive Changes CI
Sernova Corp. Appoints Cynthia Pussinen as Chief Executive Officer CI
Sernova Corp Appoints Modestus Obochi as Chief Business Officer CI
Sernova Corp. Reports Updated Interim Phase 1/2 Clinical Data for Cell Pouch System at American Diabetes Association Meet MT
Sernova Corp. Brief: Announcing "Positive" Updated Interim Phase 1/2 Clinical Data for the Cell Pouch System at American Diabetes Association 83rd Scientific Sessions MT
Sernova Corp. Announces Positive Updated Interim Phase 1/2 Clinical Data for the Cell Pouch Systemâ„¢? at American Diabetes Association 83rd Scientific Sessions CI
Sernova Corp. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2023 CI
Sernova Corp. Announces Executive Changes CI
ADRs End Mostly Lower; Sernova Gains on AstraZeneca Collaboration DJ
Toronto Stocks Flat After Tuesday's Decline; Loblaw Shares Slide as 1Q Profit Falls, Revenue Misses DJ
Sernova Shares Jump With AstraZeneca Collaboration DJ
AstraZeneca Teams Up With Sernova to Develop Therapeutic Cell Technologies MT
Sernova, AstraZeneca to Collaborate to Evaluate Potential Therapeutic Cell Applications DJ
Chart Sernova Corp.
More charts
Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology lead asset, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
0.43 CAD
Average target price
3.025 CAD
Spread / Average Target
+603.49%
Consensus
  1. Stock Market
  2. Equities
  3. SVA Stock
  4. News Sernova Corp.
  5. Sernova, Evotec "On Track" to Initiate Clinical Testing of First iPSC-Derived Islets in Cell Pouch For Type 1 Diabetes